Clinical management for epidermolysis bullosa dystrophica

Oliveira, Thais M; Sakai, Vivien T; Candido, Liliani A; Silva, Salete M. B; Machado, Maria Aparecida A. M.
J. appl. oral sci ; 16(1): 81-85, Jan.-Feb. 2008. ilus
Artigo em Inglês | LILACS | ID: lil-472695

Documentos relacionados

  1. Herpes simplex virus gene therapy for dystrophic epidermolysis bullosa (DEB).
  2. Ocular Gene Therapy in a Patient with Dystrophic Epidermolysis Bullosa.
  3. Cas9-guided haplotyping of three truncation variants in autosomal recessive disease.
  4. Future applications of 3D bioprinting: A promising technology for treating recessive dystrophic epidermolysis bullosa.
  5. Splicing Modulation via Antisense Oligonucleotides in Recessive Dystrophic Epidermolysis Bullosa.
  6. Beremagene geperpavec (B-VEC) gene therapy for the treatment of cutaneous wounds in patients with dystrophic epidermolysis bullosa: a critically appraised research paper.
  7. The Coming of Age of Topical Gene Therapy for Dystrophic Epidermolysis Bullosa.
  8. The utility of dermal fibroblasts in treatment of skin disorders: A paradigm of recessive dystrophic epidermolysis bullosa.
  9. Mesenchymal stromal cells in wound healing applications: role of the secretome, targeted delivery and impact on recessive dystrophic epidermolysis bullosa treatment.
  10. Cellular therapy options for genetic skin disorders with a focus on recessive dystrophic epidermolysis bullosa.